Drugs / Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV
Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06413121 | May 2024 → Mar 2025 | acute hepatitis B virus infection, diphtheria, pertussis, poliomyelitis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06413121 ↗ |
| Modality | Vaccine | “SIIPL has manufactured hexavalent combination vaccine containing diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and a reduced dose of three IPV antigens.” NCT06413121 ↗ |